{
    "id": 15075,
    "fullName": "IRS2 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "IRS2 amplification indicates an increased number of copies of the IRS2 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 8660,
        "geneSymbol": "IRS2",
        "terms": [
            "IRS2",
            "IRS-2"
        ]
    },
    "variant": "amp",
    "createDate": "12/09/2015",
    "updateDate": "05/23/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3746,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, solid tumor cell lines with IRS2 amplification demonstrated increased sensitivity to treatment with Figitumumab in culture (PMID: 24107449).",
            "molecularProfile": {
                "id": 15331,
                "profileName": "IRS2 amp"
            },
            "therapy": {
                "id": 741,
                "therapyName": "Figitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4073,
                    "pubMedId": 24107449,
                    "title": "Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24107449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3747,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines with IRS amplification demonstrated increased sensitivity to BMS-754807 in culture (PMID: 25527633).",
            "molecularProfile": {
                "id": 15331,
                "profileName": "IRS2 amp"
            },
            "therapy": {
                "id": 686,
                "therapyName": "BMS-754807",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4074,
                    "pubMedId": 25527633,
                    "title": "IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25527633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15331,
            "profileName": "IRS2 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 7204,
                    "name": "BMS-754807",
                    "profileName": "IRS2 amp"
                },
                {
                    "id": 7205,
                    "name": "Figitumumab",
                    "profileName": "IRS2 amp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}